Lenira-Plus Tablet is a combination pharmaceutical formulation containing Montelukast 10 mg and Fexofenadine 120 mg, designed for the management of allergic conditions. Montelukast, a leukotriene receptor antagonist, works by inhibiting the action of leukotrienes, which are inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema, thereby providing relief in conditions such as asthma and allergic rhinitis. Fexofenadine, a second-generation antihistamine, selectively blocks peripheral H1 histamine receptors, reducing symptoms like sneezing, nasal congestion, runny nose, and itching associated with seasonal allergic rhinitis and chronic urticaria. The combination of these two agents offers a synergistic effect by targeting multiple pathways in the allergic response, enhancing symptom control and improving patient compliance through a single dosage form. Lenira-Plus is indicated for the treatment of allergic rhinitis, chronic idiopathic urticaria, and as an adjunct in asthma management where allergy plays a significant role. It is generally well tolerated, with a low incidence of sedation due to the non-sedating profile of Fexofenadine and the targeted mechanism of Montelukast. Dosage should be as prescribed by a healthcare professional, and caution is advised in patients with hepatic impairment or known hypersensitivity to either component.